Market Intelligence, Clinical Progress, and High-Purity Reagents for iNKT-Targeted Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD1D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD1D ECD-Fc / CD1D-B2M Heterodimer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD1D Products |
| Gene Delivery | CD1D Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD1D Products |
| Benchmark Ab | Anti-CD1D Recombinant Antibody Recombinant positive control. |
View CD1D Products |
| Validator | CD1D siRNA Set For knockdown verification. |
View CD1D Products |
| Related Target A | B2M Beta-2 Microglobulin; essential chaperone required for stable CD1D folding and cell-surface expression. |
View B2M Products |
| Related Target B | CD3E CD3 epsilon; crucial component for characterizing iNKT cell engagers and bispecific T-cell engager (BiTE) activation. |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native heterodimeric conformation with B2M | Co-expressed CD1D/B2M heterodimeric proteins, HEK293 expressed for native glycosylation |
| In vitro lipid loading (e.g., alpha-GalCer) without degradation | High thermal stability, sequence-verified recombinant proteins with theoretical MW matching |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD1D therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific iNKT cell engagers and lipid-loaded nanoparticle systems. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective activation of invariant Natural Killer T (iNKT) cells to bridge innate and adaptive immunity while avoiding systemic cytokine release syndrome (CRS).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| iNKT Engagers (Bispecific) | MiNK Therapeutics, Inmune Bio | Solid Tumors, Multiple Myeloma | Heterodimer Validation (Need stable, co-expressed CD1D/B2M proteins) |
| Cell Therapy (CAR-iNKT) | Appia Bio, Aleta Biotherapeutics | Hematological Malignancies | Antigen presentation assays (Need Lentivirus for stable CD1D expression in APCs) |
| Lipid-loaded Complex | Academic institutions, Biotech startups | Autoimmune Diseases, Viral Infections | Lipid presentation assays (Need endotoxin-controlled, high-purity CD1D monomer) |